

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2019 (08.08.2019)



(10) International Publication Number
WO 2019/152423 A1

(51) International Patent Classification:
C07K 16/22 (2006.01) A61K 39/00 (2006.01)
(21) International Application Number:
PCT/US2019/015686

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:
29 January 2019 (29.01.2019)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/625,662 02 February 2018 (02.02.2018) US
62/647,123 23 March 2018 (23.03.2018) US
62/754,781 02 November 2018 (02.11.2018) US

(71) Applicants: **ONCOIMMUNE, INC.** [US/US]; 9430 Key West Avenue, Suite 113, Rockville, Maryland 20850 (US). **UNIVERSITY OF MARYLAND, BALTIMORE** [US/US]; Office of Technology Transfer, 620 W. Lexington Street, 4th Floor, Baltimore, Maryland 21201 (US).

(72) Inventors: **LIU, Yang**; 502 E. Street NE, Washington, District of Columbia 20002 (US). **ZHENG, Pan**; 502 E. Street NE, Washington, District of Columbia 20002 (US). **TANG, Fei**; 2229 Wheatley Drive, Apt. 301, Baltimore, Maryland 21207 (US). **LIU, Mingyue**; 2301 Wheatley Drive, Apt. 204, Baltimore, Maryland 21207 (US). **DEVENPORT, Martin**; 614 Still Creek Lane, Gaithersburg, Maryland 20878 (US). **DU, Xuexiang**; 511 W. Pratt St., Apt. 805, Baltimore, Maryland 21201-1651 (US). **ZHANG, Yan**; 710 Anderson Avenue, Rockville, Maryland 20850 (US).

(74) Agent: **GALANT, Ron** et al.; Polsinelli PC, 150 N. Riverside Plaza, Suite 3000, Chicago, Illinois 60606 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS

(57) Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

WO 2019/152423 A1